Literature DB >> 12952847

Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.

Lesley J Millatt1, Guy StJ Whitley, Dechun Li, James M Leiper, Helmy M Siragy, Robert M Carey, Roger A Johns.   

Abstract

BACKGROUND: Chronic hypoxia-induced pulmonary hypertension is associated with increased pulmonary expression of nitric oxide synthase (NOS) enzymes. Nevertheless, some reports have indicated decreased pulmonary production of NO in the disease. To address this paradox, we determined pulmonary concentrations of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) in the hypoxia-induced pulmonary hypertension rat model. In addition, we determined whether dysregulation of the ADMA-metabolizing enzyme dimethylarginine dimethylaminohydrolase I (DDAH I) plays a role in this disease. METHODS AND
RESULTS: Adult male rats were exposed for 1 week to either normoxia or hypoxia (10% oxygen). Lung tissues were used for Western blot analysis of endothelial NOS and DDAH I expression, measurement of lung NO and ADMA content, and in vitro assay of DDAH enzyme activity. Western blot analysis revealed a 1.9-fold increase in endothelial NOS protein and a 37% decrease in DDAH I protein in the lungs of hypoxia-exposed rats. Both pulmonary DDAH enzyme activity and NO content were significantly decreased in the hypoxic group (by 37% and 22%, respectively), but pulmonary ADMA concentrations were increased by 2.3-fold compared with the normoxic group.
CONCLUSIONS: These data demonstrate that the rat chronic hypoxia-induced pulmonary hypertension model is associated with increased pulmonary concentrations of the NOS inhibitor ADMA. Moreover, pulmonary hypertensive rats exhibit reduced pulmonary expression and activity of the ADMA-metabolizing enzyme DDAH I. The decreased DDAH I and increased ADMA concentrations may therefore contribute to pulmonary hypertension via the competitive inhibition of pulmonary NOS enzymes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952847     DOI: 10.1161/01.CIR.0000089087.25930.FF

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

1.  Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.

Authors:  Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin
Journal:  Eur J Pediatr       Date:  2010-12-01       Impact factor: 3.183

Review 2.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

3.  L-arginine infusion during resuscitation for hemorrhagic shock: impact and mechanism.

Authors:  Tania K Arora; Ajai K Malhotra; Rao Ivatury; Martin J Mangino
Journal:  J Trauma Acute Care Surg       Date:  2012-02       Impact factor: 3.313

Review 4.  Early determinants of pulmonary vascular remodeling in animal models of complex congenital heart disease.

Authors:  Sohrab Fratz; Jeffrey R Fineman; Agnes Görlach; Shruti Sharma; Peter Oishi; Christian Schreiber; Thomas Kietzmann; Ian Adatia; John Hess; Stephen M Black
Journal:  Circulation       Date:  2011-03-01       Impact factor: 29.690

5.  Asymmetric dimethylarginine does not inhibit arginase activity and is pro-proliferative in pulmonary endothelial cells.

Authors:  Bernadette Chen; Krista Strauch; Yi Jin; Hongmei Cui; Leif D Nelin; Louis G Chicoine
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-07       Impact factor: 2.557

6.  Increased asymmetric dimethylarginine levels in severe transient tachypnea of the newborn.

Authors:  D U Isik; A Y Bas; N Demirel; S Kavurt; O Aydemir; A V Kavurt; I Cetin
Journal:  J Perinatol       Date:  2016-02-11       Impact factor: 2.521

Review 7.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

8.  Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction.

Authors:  Neetu Sud; Sandra M Wells; Shruti Sharma; Dean A Wiseman; Jason Wilham; Stephen M Black
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-02       Impact factor: 4.249

9.  Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome.

Authors:  Serkan Nural; Ersin Günay; Bilal Halici; Sefa Celik; Mehmet Ünlü
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 10.  Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Authors:  Seiji Ueda; Sho-Ichi Yamagishi; Yuriko Matsumoto; Kei Fukami; Seiya Okuda
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.